Literature DB >> 24044037

Role of Hepatocyte Paraffin 1 antigen in the course of colorectal carcinogenesis.

Riham M Abu-Zeid1, Rola M Farid.   

Abstract

BACKGROUND: Few studies have reported the expression of Hepatocyte Paraffin 1 (Hep Par 1) in colorectal carcinomas with contradictory results. Reported rate of expression ranged from 4-50%. Moreover, the correlation between Hep Par 1 expression and clinicopathological parameters has not been investigated. The objective of the present study was to investigate the role of CPS1 (using Hep Par 1) in colonic carcinogenesis and characterize carcinomas which express it. MATERIAL AND
METHOD: Comparative analysis was done between Hep Par 1 expression in normal colonic mucosa (n=10), adenomatous polyps (n=29) and sporadic adenocarcinoma (n=40) and was correlated with clinicopathologic parameters.
RESULTS: Normal colonic mucosa did not express Hep Par 1. In contrast, it was expressed in dysplastic glands and neoplastic cells of well-moderately differentiated non-mucinous adenocarcinomas. Hep Par 1 was found in 47.5% of colonic carcinomas, 41.7% of polyps with high grade dysplasia (HGD) and 23.5% of polyps with low grade dysplasia (LGD). Mean Hep Par-1 score, likewise, was highest in carcinoma, high in polyps with HGD and lowest in polyps with LGD. Hep Par 1 expression inversely correlated with some conventional prognostic parameters including tumour type, grade, lymph node metastasis and AJCC stage. It did not correlate with depth of invasion or lymphovascular invasion.
CONCLUSION: Hep Par 1 (i.e. CPS1) might play an active role in initiation of dysplasia and progression of multistep colorectal carcinogenesis. However, it seems that CPS1 is not involved in invasion and tumour spread. Conversely, it might be in the play of suppressing cancer progression. These findings could have both prognostic and therapeutic applications.

Entities:  

Keywords:  Adenomatous polyp; Hep Par 1; colonic carcinoma; progression

Year:  2013        PMID: 24044037      PMCID: PMC3773077     

Source DB:  PubMed          Journal:  Int J Physiol Pathophysiol Pharmacol        ISSN: 1944-8171


  21 in total

1.  Hep Par 1 in gastric and bowel carcinomas: an immunohistochemical study.

Authors:  D Villari; R Caruso; M Grosso; E Vitarelli; M Righi; G Barresi
Journal:  Pathology       Date:  2002-10       Impact factor: 5.306

2.  Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma.

Authors:  Tad J Wieczorek; Jack L Pinkus; Jonathan N Glickman; Geraldine S Pinkus
Journal:  Am J Clin Pathol       Date:  2002-12       Impact factor: 2.493

3.  Immunoreactivity to monoclonal antibody, Hep Par 1, in human hepatocellular carcinomas according to histopathological grade and histological pattern.

Authors:  I Kumagai; T Masuda; S -i. Sato; K Ishikawa
Journal:  Hepatol Res       Date:  2001-07       Impact factor: 4.288

4.  Immunohistochemical characterization of canine hyperplastic hepatic lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to cytokeratin 7.

Authors:  J A Ramos-Vara; M A Miller; G C Johnson
Journal:  Vet Pathol       Date:  2001-11       Impact factor: 2.221

5.  Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples.

Authors:  Alessandro Lugli; Luigi Tornillo; Martina Mirlacher; Marcel Bundi; Guido Sauter; Luigi Maria Terracciano
Journal:  Am J Clin Pathol       Date:  2004-11       Impact factor: 2.493

6.  Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.

Authors:  Sanjay Kakar; Trudie Muir; Linda M Murphy; Ricardo V Lloyd; Lawrence J Burgart
Journal:  Am J Clin Pathol       Date:  2003-03       Impact factor: 2.493

7.  Hepatocyte paraffin 1 antibody does not distinguish primary ovarian tumors with hepatoid differentiation from metastatic hepatocellular carcinoma.

Authors:  Martha B Pitman; Surang Triratanachat; Robert H Young; Esther Oliva
Journal:  Int J Gynecol Pathol       Date:  2004-01       Impact factor: 2.762

Review 8.  Nitric oxide signaling in colon cancer chemoprevention.

Authors:  Chinthalapally V Rao
Journal:  Mutat Res       Date:  2004-11-02       Impact factor: 2.433

9.  Hepatocyte antigen as a marker of intestinal metaplasia.

Authors:  Peiguo G Chu; Zhong Jiang; Lawrence M Weiss
Journal:  Am J Surg Pathol       Date:  2003-07       Impact factor: 6.394

10.  Hepatocyte expressions in hepatocellular carcinomas, gastrointestinal neoplasms, and non-neoplastic gastrointestinal mucosa: its role as a diagnostic marker.

Authors:  Hye Seung Lee; Woo Ho Kim; Gyeong Hoon Kang
Journal:  J Korean Med Sci       Date:  2003-12       Impact factor: 2.153

View more
  1 in total

1.  Expression profiling of CPS1 in Correa's cascade and its association with gastric cancer prognosis.

Authors:  Xuqian Fang; Xiaoqiong Wu; Enfei Xiang; Fangxiu Luo; Qinqin Li; Qianchen Ma; Fei Yuan; Peizhan Chen
Journal:  Oncol Lett       Date:  2021-04-02       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.